Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer

BMC Cancer

Anne-Marie Mes-Masson⁴  Diane M Provencher²  Patricia N Tonin⁵  Suzanna L Arcand³  Zhen Shen³  Manon de Ladurantaye¹  Liliane Meunier¹  Nathalie Delvoye¹  Louis Cyr¹  Katia Y Caceres¹  Lise Portelance¹  Lu-Lin Wang¹  Michael CJ Quinn¹  Isabelle J Létourneau¹ 

[1]Centre de recherche du Centre hospitalier de l’Université de Montréal (CHUM)/Institut du cancer de Montréal, Montréal, Canada

[2]Division de gynécologie oncologique, Département d’obstétrique et gynécologie, Université de Montréal, Montréal, Canada

[3]The Research Institute of the McGill University Health Centre, Montréal, Canada

[4]Département de médecine, Université de Montréal, Montréal, Canada

[5]Department of Medicine, McGill University, Montréal, Canada

关键词: Ascites;    Chemotherapy;    Cell line model;    Ovarian cancer;   

Others  :  1080229
DOI  :  10.1186/1471-2407-12-379

 received in 2012-05-07, accepted in 2012-08-20,  发布年份 2012

【 摘 要 】

Background

Cell line models have proven to be effective tools to investigate a variety of ovarian cancer features. Due to the limited number of cell lines, particularly of the serous subtype, the heterogeneity of the disease, and the lack of cell lines that model disease progression, there is a need to further develop cell line resources available for research. This study describes nine cell lines derived from three ovarian cancer cases that were established at initial diagnosis and at subsequent relapse after chemotherapy.

Methods

The cell lines from three women diagnosed with high-grade serous ovarian cancer (1369, 2295 and 3133) were derived from solid tumor (TOV) and ascites (OV), at specific time points at diagnosis and relapse (R). Primary treatment was a combination of paclitaxel/carboplatin (1369, 3133), or cisplatin/topotecan (2295). Second line treatment included doxorubicin, gemcitabine and topotecan. In addition to molecular characterization (p53, HER2), the cell lines were characterized based on cell growth characteristics including spheroid growth, migration potential, and anchorage independence. The in vivo tumorigenicity potential of the cell lines was measured. Response to paclitaxel and carboplatin was assessed using a clonogenic assay.

Results

All cell lines had either a nonsense or missense TP53 mutations. The ability to form compact spheroids or aggregates was observed in six of nine cell lines. Limited ability for migration and anchorage independence was observed. The OV3133(R) cell line, formed tumors at subcutaneous sites in SCID mice. Based on IC₅₀ values and dose response curves, there was clear evidence of acquired resistance to carboplatin for TOV2295(R) and OV2295(R2) cell lines.

Conclusion

The study identified nine new high-grade serous ovarian cancer cell lines, derived before and after chemotherapy that provides a unique resource for investigating the evolution of this common histopathological subtype of ovarian cancer.

【 授权许可】

   
2012 Letourneau et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1 .

Figure 2 .

Figure 3 .

Figure 4 .

Figure 5 .

Figure 6 .

Figure 7 .

【 参考文献 】

• [1]McCluggage WG: Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology 2011, 43(5):420-432.
• [2]Soslow RA: Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol 2008, 27(2):161-174.
• [3]Meunier L, Puiffe ML, Le Page C, Filali-Mouhim A, Chevrette M, Tonin PN, Provencher DM, Mes-Masson AM: Effect of ovarian cancer ascites on cell migration and gene expression in an epithelial ovarian cancer in vitro model. Transl Oncol 2010, 3(4):230-238.
• [4]Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM: Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 1999, 6(4):373-378.
• [5]Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC: Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001, 22(2):255-288.
• [6]Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, Vergote I: Ovarian cancer. Crit Rev Oncol Hematol 2006, 60(2):159-179.
• [7]Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, Lee Y: The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007, 19(1):3-9.
• [8]Tewari KS, DiSaia PJ: Radiation therapy for gynecologic cancer. J Obstet Gynaecol Res 2002, 28(3):123-140.
• [9]Ozols RF: Challenges for chemotherapy in ovarian cancer. Ann Oncol 2006, 17(Suppl 5):v181-v187.
• [10]Gadducci A, Cosio S: Surveillance of patients after initial treatment of ovarian cancer. Crit Rev Oncol Hematol 2009, 71(1):43-52.
• [11]Verheijen RH, von Mensdorff-Pouilly S, van Kamp GJ, Kenemans P: CA 125: fundamental and clinical aspects. Semin Cancer Biol 1999, 9(2):117-124.
• [12]Garson K, Shaw TJ, Clark KV, Yao DS, Vanderhyden BC: Models of ovarian cancer–are we there yet? Mol Cell Endocrinol 2005, 239(1–2):15-26.
• [13]Provencher DM, Lounis H, Champoux L, Tetrault M, Manderson EN, Wang JC, Eydoux P, Savoie R, Tonin PN, Mes-Masson AM: Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim 2000, 36(6):357-361.
• [14]Arcand SL, Mes-Masson AM, Provencher D, Hudson TJ, Tonin PN: Gene expression microarray analysis and genome databases facilitate the characterization of a chromosome 22 derived homogeneously staining region. Mol Carcinog 2004, 41(1):17-38.
• [15]Birch AH, Quinn MC, Filali-Mouhim A, Provencher DM, Mes-Masson AM, Tonin PN: Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes. Mol Carcinog 2008, 47(1):56-65.
• [16]Cody NA, Ouellet V, Manderson EN, Quinn MC, Filali-Mouhim A, Tellis P, Zietarska M, Provencher DM, Mes-Masson AM, Chevrette M, et al.: Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p. Oncogene 2007, 26(4):618-632.
• [17]Quinn MC, Filali-Mouhim A, Provencher DM, Mes-Masson AM, Tonin PN: Reprogramming of the transcriptome in a novel chromosome 3 transfer tumor suppressor ovarian cancer cell line model affected molecular networks that are characteristic of ovarian cancer. Mol Carcinog 2009, 48(7):648-661.
• [18]Tonin PN, Hudson TJ, Rodier F, Bossolasco M, Lee PD, Novak J, Manderson EN, Provencher D, Mes-Masson AM: Microarray analysis of gene expression mirrors the biology of an ovarian cancer model. Oncogene 2001, 20(45):6617-6626.
• [19]Ouellet V, Zietarska M, Portelance L, Lafontaine J, Madore J, Puiffe ML, Arcand SL, Shen Z, Hebert J, Tonin PN, et al.: Characterization of three new serous epithelial ovarian cancer cell lines. BMC Cancer 2008, 8:152. BioMed Central Full Text
• [20]Puiffe ML, Le Page C, Filali-Mouhim A, Zietarska M, Ouellet V, Tonin PN, Chevrette M, Provencher DM, Mes-Masson AM: Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia 2007, 9(10):820-829.
• [21]Zietarska M, Maugard CM, Filali-Mouhim A, Alam-Fahmy M, Tonin PN, Provencher DM, Mes-Masson AM: Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). Mol Carcinog 2007, 46(10):872-885.
• [22]Langdon SP, Lawrie SS, Hay FG, Hawkes MM, McDonald A, Hayward IP, Schol DJ, Hilgers J, Leonard RC, Smyth JF: Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res 1988, 48(21):6166-6172.
• [23]Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, Pecorelli S: Carcinoma of the ovary. Int J Gynaecol Obstet 2003, 83(Suppl 1):135-166.
• [24]Kruk PA, Maines-Bandiera SL, Auersperg N: A simplified method to culture human ovarian surface epithelium. Lab Invest 1990, 63(1):132-136.
• [25]Lounis H, Provencher D, Godbout C, Fink D, Milot MJ, Mes-Masson AM: Primary cultures of normal and tumoral human ovarian epithelium: a powerful tool for basic molecular studies. Exp Cell Res 1994, 215(2):303-309.
• [26]Doubling Time. http://www.doubling-time.com/compute.php webcite
• [27]International Agency for Research on Cancer (IARC) TP53 Database. http://www-p53.iarc.f webcite
• [28]Oros KK, Ghadirian P, Greenwood CM, Perret C, Shen Z, Paredes Y, Arcand SL, Mes-Masson AM, Narod SA, Foulkes WD, et al.: Significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations. Int J Cancer 2004, 112(3):411-419.
• [29]Bossolasco M, Veillette F, Bertrand R, Mes-Masson AM: Human TDE1, a TDE1/TMS family member, inhibits apoptosis in vitro and stimulates in vivo tumorigenesis. Oncogene 2006, 25(33):4549-4558.
• [30]Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C: Clonogenic assay of cells in vitro. Nat Protoc 2006, 1(5):2315-2319.
• [31]Baker PM, Oliva E: Immunohistochemistry as a tool in the differential diagnosis of ovarian tumors: an update. Int J Gynecol Pathol 2005, 24(1):39-55.
• [32]Prat J: Ovarian carcinomas, including secondary tumors: diagnostically challenging areas. Mod Pathol 2005, 18(Suppl 2):S99-S111.
• [33]Tot T: Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma. Eur J Cancer 2002, 38(6):758-763.
• [34]Corney DC, Flesken-Nikitin A, Choi J, Nikitin AY: Role of p53 and Rb in ovarian cancer. Adv Exp Med Biol 2008, 622:99-117.
• [35]Lassus H, Leminen A, Lundin J, Lehtovirta P, Butzow R: Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol 2003, 91(3):504-512.
• [36]Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao DF, Wang TL, Kurman RJ, Shih Ie M: Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005, 29(2):218-224.
• [37]Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A, et al.: Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010, 221(1):49-56.
• [38]Hengstler JG, Lange J, Kett A, Dornhofer N, Meinert R, Arand M, Knapstein PG, Becker R, Oesch F, Tanner B: Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer. Cancer Res 1999, 59(13):3206-3214.
• [39]McKenzie SJ, DeSombre KA, Bast BS, Hollis DR, Whitaker RS, Berchuck A, Boyer CM, Bast RC Jr: Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. Cancer 1993, 71(12):3942-3946.
• [40]Meden H, Marx D, Rath W, Kron M, Fattahi-Meibodi A, Hinney B, Kuhn W, Schauer A: Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol 1994, 13(1):45-53.
• [41]Serrano-Olvera A, Duenas-Gonzalez A, Gallardo-Rincon D, Candelaria M, De la Garza-Salazar J: Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat Rev 2006, 32(3):180-190.
• [42]Cooke SL, Ng CK, Melnyk N, Garcia MJ, Hardcastle T, Temple J, Langdon S, Huntsman D, Brenton JD: Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene 2010, 29(35):4905-4913.
• [43]Merlo LM, Pepper JW, Reid BJ, Maley CC: Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006, 6(12):924-935.
• [44]L'Esperance S, Popa I, Bachvarova M, Plante M, Patten N, Wu L, Tetu B, Bachvarov D: Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int J Oncol 2006, 29(1):5-24.
• [45]Samouelian V, Maugard CM, Jolicoeur M, Bertrand R, Arcand SL, Tonin PN, Provencher DM, Mes-Masson AM: Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFbeta-RII, KRAS2, TP53 and/or CDNK2A. Cancer Chemother Pharmacol 2004, 54(6):497-504.
• [46]Ferrandina G, Ludovisi M, Corrado G, Carone V, Petrillo M, Scambia G: Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol 2008, 109(2):187-193.
• [47]Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A, Kristensen G, Jakobsen A, Sagae S, et al.: Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 2011, 21(2):419-423.
• [48]Herzog TJ: Recurrent ovarian cancer: how important is it to treat to disease progression? Clin Cancer Res 2004, 10(22):7439-7449.
• [49]Brigulova K, Cervinka M, Tosner J, Sedlakova I: Chemoresistance testing of human ovarian cancer cells and its in vitro model. Toxicol In Vitro 2010, 24(8):2108-2115.
• [50]Hagopian GS, Mills GB, Khokhar AR, Bast RC Jr, Siddik ZH: Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV). Clin Cancer Res 1999, 5(3):655-663.
• [51]Quinn JE, Carser JE, James CR, Kennedy RD, Harkin DP: BRCA1 and implications for response to chemotherapy in ovarian cancer. Gynecol Oncol 2009, 113(1):134-142.
• [52]Bachvarov D, L'Esperance S, Popa I, Bachvarova M, Plante M, Tetu B: Gene expression patterns of chemoresistant and chemosensitive serous epithelial ovarian tumors with possible predictive value in response to initial chemotherapy. Int J Oncol 2006, 29(4):919-933.